May & Baker Margin Expansion, Balance Sheet Strength Drive H1 Earnings Despite Flat Revenue
May & Baker Nigeria Plc delivered a fundamentally strong first-half 2026 performance, demonstrating that disciplined cost management and balance sheet optimisation can generate significant shareholder value even in a subdued revenue environment.
The company’s earnings profile reflects improving operational efficiency rather than top-line expansion, a quality likely to resonate with investors seeking resilient businesses in Nigeria’s healthcare sector.
Revenue remained largely unchanged at N19.28 billion, posting a marginal 0.02% year-on-year increase. While the lack of meaningful sales growth may temper expectations for aggressive expansion, the quality of earnings significantly improved as management extracted greater profitability from existing operations.
The standout feature of the period was cost efficiency. Cost of sales declined 8% to N11.6 billion, lifting gross profit by 15% to N7.67 billion despite stagnant revenue. The improvement suggests enhanced production efficiency, better procurement management, or a more favourable product mix.
Further reinforcing this trend, distribution, sales, and marketing expenses fell by 16.5% to N1.69 billion, enabling operating profit to surge by 36.4% to N4.59 billion—a substantial outperformance relative to revenue growth.
Below the operating line, May & Baker Nigeria strengthened its earnings quality through prudent treasury and financing decisions. Interest income more than doubled, increasing 101.2% to N483.1 million, while finance costs declined 43% to N224.7 million following a significant reduction in borrowings.
Current borrowings fell 68.8% from year-end levels, reflecting a deliberate deleveraging strategy that reduced financing pressure while enhancing financial flexibility. Consequently, profit before tax climbed 50.9% to N4.85 billion.
Profit after tax increased 46.4% to N3.2 billion, compared with N2.19 billion in the corresponding period of 2025, while earnings per share advanced by the same margin to 185.47 kobo from 126.68 kobo, reinforcing the company’s improved earnings capacity and value creation for shareholders.
The balance sheet equally reflects strengthening fundamentals. Cash and cash equivalents expanded 25.5% to N8.24 billion, providing improved liquidity, while shareholders’ equity rose 16.9% to N15.96 billion. Retained earnings increased 24.7% to N11.66 billion, underscoring the company’s growing internal capital generation and capacity to finance future expansion.
One balance sheet item deserving continued monitoring is trade payables, which rose 118.4% to N5.03 billion.
While the increase is not necessarily indicative of financial stress and may reflect extended supplier credit or higher procurement activity, sustained growth in payables without corresponding revenue acceleration could warrant closer investor scrutiny in subsequent reporting periods.
Management also demonstrated confidence in cash flow generation by increasing dividend payments to N862.6 million, compared with N690.1 million in the prior-year period. The higher payout signals a commitment to shareholder returns while maintaining sufficient capital to support operations.
From a market perspective, the results reinforce May & Baker’s investment proposition as a fundamentally improving healthcare company with expanding profitability, stronger liquidity, lower leverage and disciplined capital allocation.
Although investors may remain cautious over the absence of meaningful revenue growth, the market often rewards sustainable margin expansion and stronger returns on capital, particularly in defensive sectors such as pharmaceuticals.
Looking ahead, sustaining earnings momentum will increasingly depend on management’s ability to complement its operational efficiencies with stronger revenue growth.
Cost optimisation has significantly enhanced profitability, but future valuation re-rating will likely require evidence of expanding market share, increased product penetration and stronger top-line performance.
Overall, May & Baker Nigeria’s first-half 2026 results present a compelling narrative of earnings quality rather than revenue momentum.
The combination of wider margins, improving cash generation, lower financing costs and enhanced shareholder returns strengthens its valuation case within Nigeria’s healthcare sector and positions the company favourably for investors focused on long-term fundamental value. #May & Baker Margin Expansion, Balance Sheet Strength Drive H1 Earnings Despite Flat Revenue# May & Baker Shareholders Approve N690.09m Total Dividend for 2024
